Small molecular therapies for rheumatoid arthritis: Where do we stand?

Expert Opinion on Investigational Drugs

Volumn 21, Issue 1, 2012, Pages 23-31

  Cohen, Stanley ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Janus kinases; Rheumatoid arthritis; Small molecules; Spleen tyrosine kinases

Indexed keywords

ADALIMUMAB; APREMILAST; COLONY STIMULATING FACTOR 1; DOXYCYCLINE; FOSTAMITINIB; HYDROXYCHLOROQUINE; JANUS KINASE INHIBITOR; LEFLUNOMIDE; LX 3305; METHOTREXATE; MINOCYCLINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PREDNISONE; PROTEIN KINASE SYK INHIBITOR; SALAZOSULFAPYRIDINE; SPHINGOSINE 1 PHOSPHATE; TOFACITINIB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANEMIA; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; LEUKOPENIA; LIVER FUNCTION TEST; NAUSEA; NEUTROPENIA; NONHUMAN; PNEUMOCOCCAL INFECTION; PNEUMONIA; PSORIASIS; PSORIATIC ARTHRITIS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOKINES; DRUG DESIGN; HUMANS; INFLAMMATION MEDIATORS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84555217923     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.622748     Document Type: Review

References (38)

1. Goekoop-Ruiterman YP, de Vries-Bouwstra J, Allaart A, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt Study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90 (Pubitemid 41612204)
2. Verstappen SM, Jacobs JW, Van D, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA). Ann Rheum Dis 2007; 66:34-45
3. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37 (Pubitemid 43122183)
4. Genovese MC, Mckay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80
5. Klareskog L, van der Heidje D, de Jager J et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double blind randomized controlled trial. Lancet 2004;363:675-81 (Pubitemid 38296553)
6. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76 (Pubitemid 46768126)
7. Weinblatt M, Bathon J, Kremer J, et al. Safety and efficacy of etanercept beyond 10 years of therapy in north American patients with active rheumatoid arthritis. Arthritis Care Res 2010;63:373-82
8. Hetland M, Christensen J, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32
9. Hill RJ, Dabbagh K, Phippard D, et al. Pamapimod, a novel p38 MAP kinase inhibitor: preclinical analysis of the efficacy and selectivity. J Pharmacol Exp Ther 2008. [Epub ahead of print]
10. Nishikawa M, Myoui A, Tomita T, et al. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 2003;48:2670-81 (Pubitemid 37129445)
11. Genovese MC, Cohen SB, Wofsy D, et al. A randomized, double-blind, placebo controlled phase 2 study of an oral p38a MAPK inhibitor, SCIO-469, in patients with active rheumatoid arthritis. J Rheumatol 2011;38(5):846-54
12. Cohen SB, Cheng TT, Chindalore V, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:1232-41
13. Genovese M. Inhibition of p38: has the fat lady sung? Arthritis Rheum 2009;60:317-20
14. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune signaling. Immunol Rev 2009;228:273-87
15. Pesu M, Candotti F, Husa M, et al. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 2005;203:127-42 (Pubitemid 40179698)
16. Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 2009;10:356-60
17. Levine RL, Steensma D, Dewald G, et al. Activating mutation in the tyrosine kinase Jak2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97 (Pubitemid 40544655)
18. Druker BJ, Guilhot F, O'Brien S, et al. Five year followup of patients receiving imitinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17 (Pubitemid 44903745)
19. Tokumasa N, Suto A, Kagami S, et al. Expression of Tyk2 in dendritic cells is required for IL-12, IL-23 and IFN-gamma production and the induction of Th1 cell differentiation. Blood 2007;110:53-560
20. Changelian PS, Moshinsky D, Kuhn CF, et al. The Specificity of Jak3 kinase inhibitors. Blood 2007;111:2155-7 (Pubitemid 351451528)
21. Ghoreschi K, Jesson M, Li X, et al. Modulation of innate and adaptive immunity responses by tofacitinib. J Immunol 2011; 186:4234-43
22. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a Jak inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo controlled phase 11a trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-905
23. Fleischmann R, Genovese M, Gruben D, et al. Safety and efficacy after 24 week dosing of the inhibitor CP-690,550 as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheum 2009;60
24. Kremer JM, Cohen S, Wilkinson B, et al. Safety and Efficacy after 24 week dosing of the oral JAK inhibitor CP-690,550, an orally active janus kinase inhibitor in combination with methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum 2009;60
25. Kremer J, G-Li Z, Hall S, et al. Tofacitinib (CP-690,550), an oral Jak inhibitor, in combination with traditional DMARDs: phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDs. Ann Rheum Dis 2011;70:Suppl 3
26. Williams W, Schefle P, Shi J, et al. A Randomized placebo controlled trial of INCB018424, a selective janus kinase 1&2 inhibitor in rheumatoid arthritis. Arthritis Rheum 2008;58:S431
27. Hammaker D, Firestein GS. "Go Upstream, young man" lessons learnt form the p38 saga. Ann Rheum Dis 2010;69(Suppl 1):77-82
28. Cha HS, Boyle DS, Inoue T, et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006;317:571-8
29. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid Arthritis with a Syk inhibitor. Arthritis Rheum 2008;58:3309-18
30. Weinblatt ME, Kavanaugh A, Genovese MC, et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010;363:1303-12
31. Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase in the treatment of rheumatoid arthritis-A three-month randomized, placebo controlled, phase 11 study in Patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011;63:337-45
32. Lai W, Irwan AW, Goh HH, et al. Anti-inflammatory effects of sphingosine kinase modulation in inflammatory arthritis. J Immunol 2008;181:8010-17
33. Fleischmann R, Poiley J, Stoilov R, et al. The oral S1P lyase inhibitor LX3305 (A. K.A. LX2931) demonstrates favorable safety and potential clinical benefit at 12-weeks in a phase 2 proof-of-concept trial in patients with active rheumatoid arthritis on stable methotrexate therapy. Ann Rheum Dis 2011;70(Suppl3):87
34. Campbell IK, Rich MJ, Bischof RJ, et al. The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF. J Leucocyte Biol 2000;68:144-50
35. Kitaura H, Zhou P, Ju Kim H, et al. M-CSF mediated TNF-induced inflammatory osteolysis. J Clin Invest 2005;115:3418-27 (Pubitemid 43121830)
36. Semmler J, Wachtel H, Endres S. The specific type IV phosphodiesterase inhibitor rilopram suppresses tumor necrosis factor-alpha production by human mononuclear cells. Int J Immunopharmacol 1993;15:409-13 (Pubitemid 23153552)
37. Schett G, Wollenhaupt J, Papp K, et al. Apremilast is active in the treatment of rheumatoid arthritis [abstract 1258]. Arthritis Rheum 2009;60:S10
38. McCann F, Palfreeman A, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumor necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther 2010;12:R107-18